BC
ANIP icon

Bayforest Capital’s ANI Pharmaceuticals ANIP Stock Holding History

Bayforest Capital’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.4K Sell
270
-1,460
-84% -$117K 0.02% 772
2026
Q1 		$133K Buy
+1,730
New +$135K 0.15% 262

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bayforest Capital's ANIP Position: Q2 2026 in Review

Bayforest Capital reduced its ANI Pharmaceuticals (ANIP) stake by 84% in Q2 2026, selling an estimated $117K and leaving 270 shares worth $22.4K. The position accounts for 0.02% of the portfolio, ranked #772.

Bayforest Capital first reported a position in ANIP in Q1 2026 and has held it in 2 quarters since. The position peaked at $133K in Q1 2026. 308 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Bayforest Capital held 270 shares of ANI Pharmaceuticals worth $22.4K as of Q2 2026.
  • Bayforest Capital sold 1,460 ANI Pharmaceuticals shares in Q2 2026, an estimated $117K.
  • ANI Pharmaceuticals made up 0.02% of Bayforest Capital's portfolio in Q2 2026, its #772 holding.
  • Bayforest Capital first reported a position in ANI Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Bayforest Capital's ANI Pharmaceuticals position peaked at $133K in Q1 2026.
  • 308 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.